首页> 外文期刊>PLoS Medicine >Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis
【24h】

Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis

机译:英国一般实践中预防药物处方不足和中风和短暂性脑缺血发作的一级预防:回顾性分析

获取原文
           

摘要

Background Stroke is a leading cause of death and disability; worldwide it is estimated that 16.9 million people have a first stroke each year. Lipid-lowering, anticoagulant, and antihypertensive drugs can prevent strokes, but may be underused. Methods and Findings We analysed anonymised electronic primary care records from a United Kingdom (UK) primary care database that covers approximately 6% of the UK population. Patients with first-ever stroke/transient ischaemic attack (TIA), ≥18 y, with diagnosis between 1 January 2009 and 31 December 2013, were included. Drugs were considered under-prescribed when lipid-lowering, anticoagulant, or antihypertensive drugs were clinically indicated but were not prescribed prior to the time of stroke or TIA. The proportions of strokes or TIAs with prevention drugs under-prescribed, when clinically indicated, were calculated. In all, 29,043 stroke/TIA patients met the inclusion criteria; 17,680 had ≥1 prevention drug clinically indicated: 16,028 had lipid-lowering drugs indicated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs. At least one prevention drug was not prescribed when clinically indicated in 54% (9,579/17,680) of stroke/TIA patients: 49% (7,836/16,028) were not prescribed lipid-lowering drugs, 52% (1,647/3,194) were not prescribed anticoagulant drugs, and 25% (1,740/7,008) were not prescribed antihypertensive drugs. The limitations of our study are that our definition of under-prescribing of drugs for stroke/TIA prevention did not address patients’ adherence to medication or medication targets, such as blood pressure levels. Conclusions In our study, over half of people eligible for lipid-lowering, anticoagulant, or antihypertensive drugs were not prescribed them prior to first stroke/TIA. We estimate that approximately 12,000 first strokes could potentially be prevented annually in the UK through optimal prescribing of these drugs. Improving prescription of lipid-lowering, anticoagulant, and antihypertensive drugs is important to reduce the incidence and burden of stroke and TIA.
机译:背景中风是导致死亡和残疾的主要原因。据估计,全世界每年有1690万人患有中风。降脂,抗凝和降压药可以预防中风,但可能未得到充分利用。方法和发现我们分析了来自英国(UK)初级保健数据库的匿名电子初级保健记录,该数据库覆盖了英国大约6%的人口。纳入首次确诊于2009年1月1日至2013年12月31日之间的中风/短暂性脑缺血发作(TIA)≥18岁的患者。当临床上指示使用降脂药,抗凝药或降压药但在中风或TIA之前未开药时,则认为药物处方不足。当临床上有指示时,计算了中风或TIA与处方药不足的预防药物的比例。共有29,043名卒中/ TIA患者符合纳入标准;临床上有≥1种预防药物为17,680例;有16028种为降脂药物,3,194种抗凝药和7,008种降压药。当54%(9,579 / 17,680)的中风/ TIA患者在临床上未指定至少一种预防药物的处方:49%(7,836 / 16,028)的患者未处方降脂药物,52%(1,647 / 3,194)的患者未处方抗凝药物,其中25%(1,740 / 7,008)未开抗高血压药。我们研究的局限性在于我们对预防中风/ TIA的药物处方不足的定义并未解决患者对药物或药物目标(例如血压水平)的依从性。结论在我们的研究中,超过一半的符合降脂,抗凝或降压药物资格的人在首次卒中/ TIA之前未开处方。我们估计,通过最佳处方这些药物,英国每年可能可以预防约12,000次中风。改善降脂,抗凝和降压药物的处方对于降低中风和TIA的发生率和负担很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号